Local Treatment of Non-small Cell Lung Cancer with a Spray-Dried Bevacizumab Formulation
Autor: | David Revelli, Jonathan L. Cape, Lauren Switala, Amanda M. Pluntze, John M. Baumann, Michael Banks, Yue Zhou, Philip J. Kuehl, Kimberly B. Shepard, Julia C. Oddo, Molly S. Adam, David T. Vodak |
---|---|
Rok vydání: | 2021 |
Předmět: |
Lung Neoplasms
Bevacizumab Pharmaceutical Science Aquatic Science Pharmacology Antineoplastic Agents Immunological In vivo Carcinoma Non-Small-Cell Lung Administration Inhalation Drug Discovery medicine Animals biotherapeutics spray drying Particle Size Lung cancer Ecology Evolution Behavior and Systematics Aerosols Spray dried Lung Ecology Inhalation business.industry Dry Powder Inhalers General Medicine medicine.disease respiratory tract diseases Rats lung cancer medicine.anatomical_structure monoclonal antibody Spray drying Non small cell Powders business Agronomy and Crop Science local delivery Research Article medicine.drug |
Zdroj: | AAPS PharmSciTech |
ISSN: | 1530-9932 |
Popis: | Local delivery of biotherapeutics to the lung holds great promise for treatment of lung diseases, but development of physically stable, biologically active dry powder formulations of large molecules for inhalation has remained a challenge. Here, spray drying was used to manufacture a dry powder pulmonary formulation of bevacizumab, a monoclonal antibody approved to treat non-small cell lung cancer (NSCLC) by intravenous infusion. By reformulating bevacizumab for local delivery, reduced side effects, lower doses, and improved patient compliance are possible. The formulation had aerosol properties suitable for delivery to the deep lung, as well as good physical stability at ambient temperature for at least 6 months. Bevacizumab’s anti-VEGF bioactivity was not impacted by the manufacturing process. The formulation was efficacious in an in vivo rat model for NSCLC at a 10-fold decrease in dose relative to the intravenous control. |
Databáze: | OpenAIRE |
Externí odkaz: |